Company Analysis
Sign in

SAB Biotherapeutics, Inc. (SABS)

Nasdaq: SABS · Biological Products, (No Diagnostic Substances) · Miami Beach, FL · filing with the SEC since 2020
Full chart Alerts Compare
Grade3.9
◀ Past 2.1● Present 4.6▶ Future 4.5
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$0.00-100.0%
Net income$13.3M+138.9%
Earnings per share$-0.79+78.5%
Operating cash flow-$44.8M-30.6%
Cash$10.5M+18.0%
Debtn/a
Shareholders’ equity$151M+483.4%
Shares, diluted61.3M+562.3%
Return on equity8.8%
The recordfrom its filings
Filings in 202651
Newest filingNov 5 · 10-Q
Annual reportMar 9, 2026
Quarterly reportNov 5, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted6
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Trailing twelve months to Sep 2026Net income -$80.5MCash from operations -$53.9Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 5, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Oct 13, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 18, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Aug 21, 2026 · SEC EDGAR · Form 424B3
Shelf offering
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton SABS · research, not advice